Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (291-300 of 578) with videos related to

Pageof 58
Sort By:
Carcinogenesis|October 6, 2019
miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional studyKonstantina Panoutsopoulou, Margaritis Avgeris, Konstantinos Mavridis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2016
Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal MassesAdriaan Vanderstichele, Pieter Busschaert, Dominiek Smeets, et al.
Cancer Science|April 14, 2012
Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD ConsortiumDietmar Pils, Gudrun Hager, Dan Tong, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 6, 2023
Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutionsThomas J Herzog, Shaun A Wahab, Mansoor R Mirza, et al.
Cancer|July 23, 2003
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trialsJohn F R Robertson, C Kent Osborne, Anthony Howell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
In utero exposure to chemotherapy: effect on cardiac and neurologic outcomeKristel Van Calsteren, Patrick Berteloot, Myriam Hanssens, et al.
Genome Medicine|July 9, 2021
High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classificationSiel Olbrecht, Pieter Busschaert, Junbin Qian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?Leen De Maeyer, Erik Van Limbergen, Katelijne De Nys, et al.
Gynecologic Oncology|July 20, 2024
Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012Mitchell R Kamrava, Antonio Gonzalez-Martin, Bhavana Pothuri, et al.
Gynecologic Oncology|July 13, 2021
Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective studyJasper Victoor, Sara Vander Borght, Lien Spans, et al.
Pageof 58

Showing results (291-300 of 578) with videos related to

Sort By:
Pageof 58
Carcinogenesis|October 6, 2019
miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional studyKonstantina Panoutsopoulou, Margaritis Avgeris, Konstantinos Mavridis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2016
Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal MassesAdriaan Vanderstichele, Pieter Busschaert, Dominiek Smeets, et al.
Cancer Science|April 14, 2012
Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD ConsortiumDietmar Pils, Gudrun Hager, Dan Tong, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 6, 2023
Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutionsThomas J Herzog, Shaun A Wahab, Mansoor R Mirza, et al.
Cancer|July 23, 2003
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trialsJohn F R Robertson, C Kent Osborne, Anthony Howell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
In utero exposure to chemotherapy: effect on cardiac and neurologic outcomeKristel Van Calsteren, Patrick Berteloot, Myriam Hanssens, et al.
Genome Medicine|July 9, 2021
High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classificationSiel Olbrecht, Pieter Busschaert, Junbin Qian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?Leen De Maeyer, Erik Van Limbergen, Katelijne De Nys, et al.
Gynecologic Oncology|July 20, 2024
Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012Mitchell R Kamrava, Antonio Gonzalez-Martin, Bhavana Pothuri, et al.
Gynecologic Oncology|July 13, 2021
Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective studyJasper Victoor, Sara Vander Borght, Lien Spans, et al.
Pageof 58